Tumor therapy with a PD-1 inhibitor caused adverse effects similar to the symptoms of GO and exogenous PD-L1 reduced orbital inflammation of fibroblasts by inhibiting T cell activity (Sagiv et al., 2019; Liu et al., 2022). The gene discussed is CD274; the disease is neoplasm.